Mantle Cell Lymphoma Market

SKU: DMPH2172 | Last Updated On: Sep 15 2022 | Available Formats

> Mantle Cell Lymphoma Market Expected to reach a high CAGR of 7% By 2029 : DataM Intelligence

Mantle Cell Lymphoma Market is segmented By Therapy type (Targeted Therapy, Chemotherapy, Radiotherapy, Others), By Route of administration (Oral, Intravenous, others), By End-user (hospitals, clinics,others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Mantle Cell Lymphoma Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7% during the forecast period (2022-2029).

Mantle Cell Lymphoma Market Scope

Metrics

Details

Market CAGR

7%

Segments Covered

By Therapy Type, By Route of Administration, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into Market, Get Our Sample Brochure

Mantle cell lymphoma (MCL) is a rare type of blood cancer due to the excessive growth of lymphocytes. Mantle cell lymphoma (MCL) is one of the B-cell non-Hodgkin lymphomas, which occur due to the formation of tumors in the lymph nodes, which enter the blood and spread to the bone marrow, spleen, digestive tract, and liver.

Market Dynamics

The major driving forces are the growing prevalence of mantle cell lymphoma and increasing research & development activities in the healthcare sector resulting in a robust product pipeline.

The presence of ongoing research and development activities is expected to drive market growth.

The promising mantle cell lymphoma pipeline will drive market growth over the forecast period. For instance, AstraZeneca has sponsored a prospective disease registry of patients with mantle cell lymphoma treated with novel agents and is anticipated to be completed on March 20, 2024; a Phase 2 trial to assess the efficacy of bortezomib, cytarabine, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma, sponsored by Seoul National University Hospital and is anticipated to be launched in June 2025, a Phase I/II study of ixazomib and ibrutinib in relapsed/refractory mantle cell lymphoma sponsored by PrECOG, LLC. In collaboration with Takeda and anticipated to be completed in December 2024 and a Multicenter Phase II study of ixazomib maintenance in patients with newly diagnosed mantle cell lymphoma, Kosin University Gospel Hospital, in collaboration with Takeda sponsored and expected launch is in December 2022.

The high development cost and the onset of side effects are expected to hinder global mantle cell lymphoma market growth.

However, serious side effects of drugs like anemia, neutropenia, and diarrhea are restraining market growth.

Industry analysis.

The global mantle cell lymphoma market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

COVID-19 Impact Analysis

COVID-19 has significantly impacted the global mantle cell lymphoma market. Because of the COVID-19 containment protocols, the supply chain of many market players was disrupted and caused a lack of raw materials, which disturbed the supply and demand chain. Furthermore, due to the socializing restrictions, regular healthcare checkups were difficult, leaving most patients with mantle cell lymphoma undetected, negatively impacting the global mantle cell lymphoma market growth during the pandemic.

Segment Analysis

The targeted therapy segment is assumed to command the Mantle Cell Lymphoma market throughout the forecast period (2022-2029).

The targeted therapy segment is expected to grow rapidly over the forecast period (2022-2029). Developing targeted agents with low toxicity profiles for treating relapsed mantle cell lymphoma (MCL) in combination with approved drugs is a major factor in augmenting the mantle cell lymphoma treatment market growth. The introduction of the novel targeted agent’s ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta), among others, is rapidly changing the relapsed/refractory space of the mantle cell lymphoma (MCL) and the upfront setting of chronic lymphocytic leukemia (CLL), according to James N. Gerson, MD. For instance, a Phase II study of bendamustine and rituximab plus venetoclax in untreated mantle cell lymphoma over 60 years of age by PrECOG, LLC. In collaboration with Genentech, Inc., expected to be completed by March 2025 and a Pilot Study of acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab for untreated mantle cell lymphoma by Washington University School of Medicine in collaboration with Acerta Pharma BV estimated to be completed by November 2025.

Geographical Analysis

The North American region holds the largest market share of the global Mantle Cell Lymphoma market.

North America dominated the global mantle cell lymphoma market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the presence of key market players in North America and their hold over the global market with increasing research and development activities. For instance, on July 24, 2020, a U.S.-based company, Kite, A Gilead Company. LLS secured the approval for its brexucabtagene autoleucel (formerly KTE-X19, now branded as Tecartus) as the first chimeric antigen receptor (CAR) T-cell therapy approved for patients with MCL. Furthermore, according to the rare disease organization, MCL usually occurs at 60 to 70 years old, and since the United States has a large pool of geriatric population is expected to dominate the global market. According to the U.S. Census Bureau estimation, over 54 million adults aged 65 and older in 2020 made up 16.5% of the total United States population, estimated to reach 85.7 million by 2050, accounting for 20% of the total United States Population.

Competitive Landscape

The major players operating in the global mantle cell lymphoma market are F. Hoffman La Roche Ltd, Abbvie, Inc., Kite Pharma, Inc. (Gilead Sciences, Inc.), Celgene Corporation, Eli Lilly and Company, Amgen, Inc., Takeda Pharmaceutical Co. Ltd, AstraZeneca Plc, and Johnson and Johnson. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the global growth of the mantle cell lymphoma market. For instance, on 16 August 2022, FDA accepted the supplemental Biologics License Application for Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma. Also, on July 27, 2021, AbbVie and Calico announced the extension of collaboration focused on aging and age-related diseases.

Kite Pharma, Inc. (Gilead Sciences, Inc.)

Overview:

Kite Pharma is a branch of Gilead Sciences, Inc. Kite Pharma was established in 2009 with its headquarters in California, United States. Kite Pharma is a leading American biotechnology company involved in developing cancer immunotherapy products that are majorly focused on the genetically-engineered autologous T cell therapy with chimeric antigen receptors.

Product Portfolio:

 The Kite Pharma, Inc. (Gilead Sciences, Inc.) product portfolio for mantle cell lymphoma contains Tecartus.

The global mantle cell lymphoma market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Trending Topics

T-cell-lymphoma Market

Hodgkin’s Lymphoma Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest